Drug
Seribantumab clinical trials
Also written MM-121 and SAR256212.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Merrimack Pharmaceuticals (7) · Elevation Oncology (3) · Ottawa Hospital Research Institute (1) · Sanofi (1)
Often tested with
Tested in the same studies.
Paclitaxel (1) · XL147 (1) · Istiratumab (1) · Trametinib (1)
Studies
Open first, then newest update. How each study uses seribantumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsTerminatedPhase 2Elevation OncologyNCT04383210Written as Seribantumab
- Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using SeribantumabCompletedPhase 2Ottawa Hospital Research InstituteNCT04790695Written as Seribantumab
- A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCTerminatedPhase 2Elevation OncologyNCT02387216Written as MM-121
- Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerTerminatedPhase 2Elevation OncologyNCT03241810Written as Seribantumab
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedPhase 1Merrimack PharmaceuticalsNCT02538627Written as MM-121
- A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersCompletedPhase 1Merrimack PharmaceuticalsNCT01209195Written as MM-121
- Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedPhase 1Merrimack PharmaceuticalsNCT00734305Written as MM-121
- A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 1/2Merrimack PharmaceuticalsNCT00994123Written as MM-121
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerCompletedPhase 2Merrimack PharmaceuticalsNCT01151046Written as MM-121
- A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedPhase 2Merrimack PharmaceuticalsNCT01447706Written as MM-121
- A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerCompletedPhase 2Merrimack PharmaceuticalsNCT01421472Written as MM-121
- A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor CancersCompletedPhase 1SanofiNCT01436565Written as MM-121 (SAR256212)
Given in every arm · 2 — seribantumab is usual care beside what is tested
- Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsCompletedPhase 1Merrimack PharmaceuticalsNCT01447225Written as MM-121
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersCompletedPhase 1Merrimack PharmaceuticalsNCT01451632Written as MM-121
Codes
What other systems call seribantumab · ClinicalTrials.gg INT000024
- MeSH (NLM) C000589319seribantumabOne source NLM
- UNII (FDA) 1N3L70MDFXSERIBANTUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q19946112seribantumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78859SeribantumabOne source FDA
- DrugBank DB11857One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589319 | seribantumab | One source NLM |
| UNII (FDA) | 1N3L70MDFX | SERIBANTUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19946112 | seribantumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78859 | Seribantumab | One source FDA |
| DrugBank | DB11857 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.